These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17464949)

  • 1. Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
    Chugh R; Wagner T; Griffith KA; Taylor JM; Thomas DG; Worden FP; Leu KM; Zalupski MM; Baker LH
    Cancer; 2007 Jun; 109(11):2315-22. PubMed ID: 17464949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).
    Cerny T; Leyvraz S; von Briel T; Küpfer A; Schaad R; Schmitz SF; Honegger P; Sessa C; Brunner J; Boddy AV
    Ann Oncol; 1999 Sep; 10(9):1087-94. PubMed ID: 10572607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
    Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
    Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
    Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
    Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.
    Di Marco MP; Wainer IW; Granvil CL; Batist G; Ducharme MP
    Pharm Res; 2000 Jun; 17(6):645-52. PubMed ID: 10955835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes.
    Granvil CP; Madan A; Sharkawi M; Parkinson A; Wainer IW
    Drug Metab Dispos; 1999 Apr; 27(4):533-41. PubMed ID: 10101149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
    Kerbusch T; de Kraker J; Keizer HJ; van Putten JW; Groen HJ; Jansen RL; Schellens JH; Beijnen JH
    Clin Pharmacokinet; 2001 Jan; 40(1):41-62. PubMed ID: 11236809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
    Baranzelli MC; Pichon F; Gourmel B; N'Guyen M; Deligny N; Demaille MC
    Bull Cancer; 1997 Feb; 84(2):141-6. PubMed ID: 9180836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
    Paine MF; Wagner DA; Hoffmaster KA; Watkins PB
    Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An original administration of ifosfamide given once every other week: a clinical and pharmacological study.
    Cacheux W; Gourmel B; Alexandre J; Germann N; Rabillon F; Duffau B; Goldwasser F
    Anticancer Drugs; 2008 Mar; 19(3):295-302. PubMed ID: 18510176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
    Chen LK; Xu GC; Teng XY; Liang Y; Liu JL; Zhou XM
    Ai Zheng; 2002 Aug; 21(8):903-6. PubMed ID: 12478904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies.
    Lopez AM; Ketchum M; Nichols H; Xu MJ; Peng YM; Dorr R; Alberts DS
    Cancer Chemother Pharmacol; 2000; 46(5):411-5. PubMed ID: 11127946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole.
    Jamis-Dow CA; Pearl ML; Watkins PB; Blake DS; Klecker RW; Collins JM
    Am J Clin Oncol; 1997 Dec; 20(6):592-9. PubMed ID: 9391548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
    Michael M; Cullinane C; Hatzimihalis A; O'Kane C; Milner A; Booth R; Schlicht S; Clarke SJ; Francis P
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):125-35. PubMed ID: 21626050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
    Kerbusch T; Huitema AD; Ouwerkerk J; Keizer HJ; Mathôt RA; Schellens JH; Beijnen JH
    Br J Clin Pharmacol; 2000 Jun; 49(6):555-61. PubMed ID: 10848719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans.
    Mouly S; Lown KS; Kornhauser D; Joseph JL; Fiske WD; Benedek IH; Watkins PB
    Clin Pharmacol Ther; 2002 Jul; 72(1):1-9. PubMed ID: 12151999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
    Boddy AV; English M; Pearson AD; Idle JR; Skinner R
    Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n = 1 randomized study.
    Brain EG; Rezai K; Lokiec F; Gutierrez M; Urien S
    Br J Clin Pharmacol; 2008 Apr; 65(4):607-10. PubMed ID: 18294323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
    Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
    Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
    Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
    J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.